Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 57Observational 11Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

3-Iodobenzylguanidine 2Gemcitabine 2Powders 2Suspensions 2balstilimab 2leronlimab 2ruxolitinib 2talquetamab 2Abiraterone Acetate 1Alpelisib 1Androgen Antagonists 1Asparaginase 1Bone Marrow Transplantation 1Capecitabine 1Cyclophosphamide 1Docetaxel 1Eflornithine 1FANG vaccine 1HMPL-013 1Hydrocortisone 1Immunotherapy, Adoptive 1Insulin Infusion Systems 1LY3023414 1Magnetic Resonance Spectroscopy 1Methionine 1Nivolumab 1Paclitaxel 1Peripheral Blood Stem Cell Transplantation 1Prednisolone 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × apalutamide × 1 year × Clear all
NCT03523338 2025-12-10

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals, Inc.

No longer available
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡